Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant...
Covered in this story
Call it yourself
No calls on $SAN.PA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Sanofi →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.